<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815332</url>
  </required_header>
  <id_info>
    <org_study_id>BPX-01-C03</org_study_id>
    <nct_id>NCT02815332</nct_id>
  </id_info>
  <brief_title>BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris</brief_title>
  <acronym>OPAL</acronym>
  <official_title>A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioPharmX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioPharmX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled
      study.

      Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply
      1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night
      for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be
      performed to assess efficacy.

      Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the
      level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical
      examination, clinical laboratory tests, cutaneous tolerance score, incidence of
      minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches
      suggestive of pseudotumor cerebri, and collection of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2b, randomized, double-blind, vehicle-controlled study to Assess the Safety
      and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe
      Inflammatory Acne Vulgaris.

      Study Population: Approximately 225 male or female subjects aged between 9 and 40 years with
      moderate to severe inflammatory non-nodular acne vulgaris will be included in this study.

      Number of Sites: Approximately 15 centers from the United States will participate in this
      study.

      Study Duration: Overall study duration is expected to be approximately 24 weeks (6 months).
      The study duration for individual subjects is approximately 16 weeks (including the screening
      period).

      Hypothesis: BPX-01 improves disease condition in subjects with moderate to severe
      inflammatory non-nodular acne vulgaris compared with vehicle.

      Objectives:

      Primary:

        -  To evaluate the efficacy of BPX-01 minocycline 1% or 2% topical gel in the treatment of
           inflammatory non-nodular acne vulgaris

      Secondary:

        -  To evaluate the plasma level of minocycline after once daily application of 1% or 2% BPX
           01 topical gel

        -  To evaluate the safety of BPX-01 minocycline 1% or 2% topical gel

      Endpoints:

      Primary Efficacy Endpoint:

        -  Absolute mean change from baseline in inflammatory lesion counts at Week 12

      Secondary Efficacy Endpoint:

        -  Proportion of subjects with at least a two-grade reduction in IGA at Week 12
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">March 24, 2017</completion_date>
  <primary_completion_date type="Actual">March 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute mean change from baseline in inflammatory lesion counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in IGA</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of subjects with at least a two-grade reduction in IGA from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BPX-01 Vehicle Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPX-01 1% Minocycline Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPX-01 2% Minocycline Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPX-01 1% Minocycline Topical Gel</intervention_name>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
    <arm_group_label>BPX-01 1% Minocycline Topical Gel</arm_group_label>
    <other_name>BPX-01 Topical Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPX-01 2% Minocycline Topical Gel</intervention_name>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
    <arm_group_label>BPX-01 2% Minocycline Topical Gel</arm_group_label>
    <other_name>BPX-01 Topical Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPX-01 Vehicle Topical Gel</intervention_name>
    <description>Approximately 1 gram applied once daily for 12 weeks</description>
    <arm_group_label>BPX-01 Vehicle Topical Gel</arm_group_label>
    <other_name>BPX-01 Vehicle Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged between 9 and 40 years of age.

          2. Subjects do not have any medical conditions, other than acne vulgaris, that in the
             opinion of the investigator, put the subject at unacceptable risk or could interfere
             with study assessments or integrity of the data.

          3. Moderate to severe inflammatory non-nodular acne vulgaris.

          4. Female subjects of childbearing potential (including pre-puberty) are willing to use
             effective contraceptive method for at least 28 days before baseline (Day 0) and at
             least 28 days after the last study product administration or have a sterilized or
             same-sex partner for the duration of the study.

          5. Treatment with hormonal therapy must be on a stable dose and frequency for at least 12
             weeks before baseline (Day 0) and must remain stable throughout the study.

          6. Subjects who use make-up, facial moisturizers, creams, or lotions, cleansers and/or
             sunscreens must have used the same product brands/types for a minimum period of 14
             days prior to baseline (Day 0), must agree not to change brand/type or frequency of
             use throughout the study and must agree not to use make-up, facial moisturizers,
             creams, or lotions, cleansers and/or sunscreens on the clinic visit days before the
             visit.

          7. Subjects must be capable of giving informed consent and the written informed consent
             must be obtained prior to any study-related procedures. Subject under 18 years of age
             must sign an assent form, and their parent(s) or legal representative must have read
             and signed the informed consent form prior to any study-related procedures.

        Exclusion Criteria:

          1. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during
             the study.

          2. Have acne fulminans or conglobata, or nodulocystic acne.

          3. Have a history of skin disease, presence of skin condition, or excessive facial hair
             that, in the opinion of the investigator, would interfere with the study.

          4. Have a history of cancer or lymphoproliferative disease other than a successfully
             treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or
             localized carcinoma in situ of the cervix.

          5. Have a history of minocycline-induced hepatitis, minocycline-induced arthritis,
             minocycline-induced lupus or minocycline/tetracycline-induced pseudotumor cerebri.

          6. Presence of minocycline-induced hyperpigmentation at screening or baseline (Day 0).

          7. Presence of visual disturbances and/or headaches suggestive of pseudotumor cerebri at
             screening or baseline (Day 0).

          8. Have a clinical chemistry or hematology laboratory value that is abnormal at the
             screening visit and that is considered clinically significant by the investigator.

          9. Has an ALT or AST at screening greater than or equal to 2 times the upper limit of
             normal.

         10. Have used on the face an over-the-counter (OTC) topical medications for the treatment
             of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications,
             corticosteroids, salicylic acid, Î±-hydroxy/glycolic, antibacterial/antiseptic soap or
             wash within 14 days prior to baseline (Day 0).

         11. Have used prescription topical retinoid (e.g. tretinoin, tazarotene, adapalene) or
             antimicrobials (e.g. clindamycin, erythromycin) or other prescription topical
             medications for the treatment of acne vulgaris within 28 days of baseline (Day 0).

         12. Have used systemic antibiotics or other systemic anti-acne drugs not mentioned in the
             exclusion criteria within 28 days of baseline (Day 0).

         13. Have used oral, intranasal, or injectable corticosteroids within 28 days of baseline
             (Day 0) or require them during the study. Inhaled corticosteroids for stable medical
             conditions are allowed.

         14. Have received an investigational therapy (including investigational drug or procedure)
             within 28 days of baseline (Day 0) or plan to use one during the study.

         15. Have had a facial procedure (e.g. chemical peel, laser, microdermabrasion) within 8
             weeks of baseline (Day 0).

         16. Have excessive sun exposure, is planning a trip to a sunny climate or used tanning
             booths within 28 days prior to baseline (Day 0) or is not willing to minimize natural
             and artificial sunlight exposure during the study.

         17. Have received photodynamic therapy or phototherapy with blue or red light within 12
             weeks of baseline (Day 0).

         18. Have used androgen receptor blockers (such as spironolactone or flutamide) within 12
             weeks of baseline (Day 0).

         19. Have used drospirenone, chlormadinone acetate, and cyproterone acetate within 26 weeks
             of baseline (Day 0).

         20. Have used oral retinoid (e.g., isotretinoin) within 52 weeks prior to baseline (Day 0)
             or vitamin A supplements greater than 10,000 U/d within 26 weeks of baseline (Day 0).

         21. History of clinically significant drug or alcohol abuse in the last year prior to
             baseline (Day 0) as judged by the investigator.

         22. Has known or suspected allergy to minocycline, tetracycline-class antibiotics or any
             component of the investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AnnaMarie Daniels</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor (BioPharmX)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Highpoint</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

